-
COST EFFECTIVENESS ANALYSIS OF ADULT PNEUMOCOCCAL VACCINES INCLUDING PCV21 AND PCV20 TO OPTIMIZE NATIONAL IMMUNIZATION PROGRAM IN JAPAN
Mar 18, 2026, 21:38 PM -
STANDARDIZING AN ANNUAL REFERENCE COMPARATOR OF HEALTHCARE UTILIZATION OF PAINFUL DIABETIC NEUROPATHY (PDPN): A U.S. CLAIMS COHORT META-ANALYSIS FOR MODELING AND PAYER BENCHMARKING
Mar 18, 2026, 21:38 PM -
CAREGIVER-DEFINED UNMET NEEDS TO SUPPORT PATIENT-CENTERED TRIAL DESIGN AND VALUE CONSIDERATIONS IN MULTIPLE SULFATASE DEFICIENCY (MSD)
Mar 18, 2026, 21:38 PM -
PRICE ANALYSIS OF GENE THERAPIES AUTHORIZED BY THE U.S. FOOD AND DRUG ADMINISTRATION
Mar 18, 2026, 21:38 PM -
TRENDS IN BACK PAIN HEALTHCARE UTILIZATION AND EXPENDITURES AMONG U.S. ADULTS: 2007 VS 2023
Mar 18, 2026, 21:38 PM -
INCREASED HEALTHCARE COSTS AND RESOURCE UTILIZATION FOLLOWING PROGRESSION IN PATIENTS WITH HR+/HER2- METASTATIC BREAST CANCER RECEIVING CHEMOTHERAPY
Mar 18, 2026, 21:38 PM -
A LIVING NETWORK META-ANALYSIS FRAMEWORK FOR COMPARATIVE EFFECTIVENESS RESEARCH IN CHRONIC VENOUS INSUFFICIENCY TREATMENT
Mar 18, 2026, 21:38 PM -
FROM NATURAL HISTORY TO POST-APPROVAL EVIDENCE: AN INTEGRATED MULTI-SOURCE REAL-WORLD PROGRAM CHARACTERIZING IGA NEPHROPATHY IN THE ERA OF ORAL TARGETED-RELEASE FORMULATION OF BUDESONIDE
Mar 18, 2026, 21:38 PM -
SUSTAINED FACTOR IX LEVELS AT 5-YEARS AFTER ETRANACOGENE DEZAPARVOVEC - THE EXPONENTIAL DECAY MODEL MAY UNDERESTIMATE OBSERVED RESULTS
Mar 18, 2026, 21:38 PM -
FUTURE-PROOFING UK HTA: CAN NICE ABSORB MFN-INDUCED PRICE INCREASES?
Mar 18, 2026, 21:38 PM -
THE ROLE OF INNOVATIVE CONTRACTS IN ADDRESSING UNMET MEDICAL NEEDS FOR HIGH-BUDGET-IMPACT THERAPIES: EVIDENCE FROM THERAPEUTIC ANALOGUES AND IMPLICATIONS FOR OBESITY
Mar 18, 2026, 21:38 PM -
AN AUTOMATED NETWORK META-ANALYSIS FRAMEWORK INTEGRATING INTELLIGENT ALGORITHMS AND LARGE LANGUAGE MODELS
Mar 18, 2026, 21:38 PM -
DEVELOPMENT OF AN INDIVIDUAL-LEVEL SIMULATION MODEL TO ASSESS THE COST CONSEQUENCES OF CARDIOVASCULAR-RENAL-METABOLIC SCREENING POLICIES FROM A NATIONAL PAYER AND SOCIETAL PERSPECTIVE
Mar 18, 2026, 21:38 PM -
A METHOD FOR CALCULATING THE TOTAL QALY OUTPUT AND THE MEAN COST/QALY ATTRIBUTABLE TO THE HEALTH SECTOR; THE CASE OF THE UK
Mar 18, 2026, 21:38 PM -
A NOVEL BIOMARKER FOR THE EARLY DETECTION OF DIABETIC KIDNEY DISEASE: A BUDGET IMPACT ANALYSIS
Mar 18, 2026, 21:38 PM -
EVIDENCE FOR MEANINGFUL PATIENT BENEFIT OF PEGCETACOPLAN IN C3G AND PRIMARY IC-MPGN FROM THE VALIANT TRIAL
Mar 18, 2026, 21:38 PM -
AUTOMATED AMCP DOSSIER DEVELOPMENT USING A RETRIEVAL-AUGMENTED GENERATION (RAG)-BASED MULTI-AGENT APPROACH
Mar 18, 2026, 21:38 PM -
CAREGIVER BURDEN AND SOCIOECONOMIC IMPACT OF HE AND OHE AMONG INDIVIDUALS CARING FOR PATIENTS WITH CIRRHOSIS
Mar 18, 2026, 21:38 PM -
FINANCIAL HARDSHIP, MEDICATION MANAGEMENT BEHAVIORS, AND PERCEIVED QUALITY OF CARE AMONG MEDICARE BENEFICIARIES
Mar 18, 2026, 21:38 PM -
APPLICATION OF CAUSAL FOREST TO IDENTIFY IMPORTANT FEATURES TO EVALUATE HETEROGENEOUS TREATMENT EFFECTS OF DISEASE-MODIFYING THERAPIES IN MULTIPLE SCLEROSIS
Mar 18, 2026, 21:38 PM
